Shot in the arm for GSK as EU  authorises its endometrial cancer treatment Jemperli

Breakthrough: GSK boss Emma Walmsley (pictured) has been pushing to boost the firm’s drug pipeline

GSK has scored another win for its drug pipeline. European watchdogs have given a cancer treatment developed by the pharma giant the thumbs up.

Jemperli has been cleared by the European Commission for use alongside chemotherapy to treat endometrial cancer, which affects the uterus.

EU regulators also green lit Jemperli for use by itself, or after chemo. It follows similar approvals for the drug in the US.

GSK head of oncology research Hesham Abdullah said: ‘With this approval, we can expand the number of patients who can potentially benefit from treatment with Jemperli in Europe.’

The drugs giant has invested heavily in Jemperli and is aiming to expand its use to several different types of cancer. 

Last month, the company’s blood cancer drug Blenrep reached a key goal in a late-stage clinical trial following a series of setbacks.

GSK boss Emma Walmsley has been pushing to boost the company’s drug pipeline after splitting off its consumer health business Haleon last year.

The strategy appears to be working, with GSK upgrading its profit guidance for the second time this year after big sales of its vaccine Arexvy, which protects against respiratory syncytial virus (RSV).